PE20232044A1 - Compuestos heterociclicos de heteroarilo y usos de los mismos - Google Patents
Compuestos heterociclicos de heteroarilo y usos de los mismosInfo
- Publication number
- PE20232044A1 PE20232044A1 PE2023001166A PE2023001166A PE20232044A1 PE 20232044 A1 PE20232044 A1 PE 20232044A1 PE 2023001166 A PE2023001166 A PE 2023001166A PE 2023001166 A PE2023001166 A PE 2023001166A PE 20232044 A1 PE20232044 A1 PE 20232044A1
- Authority
- PE
- Peru
- Prior art keywords
- independently
- halogen
- alkyl
- deuterium
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 4
- 229910052805 deuterium Inorganic materials 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a compuestos heterociclicos de heteroarilo de formula I, o una sal farmaceuticamente aceptable del mismo, solvato, mezcla racemica, enantiomero, diastereomero o tautomero del mismo, en donde X1, X2 y X3 son cada uno independientemente CH o N; U y V son cada uno independientemente N o CR9; Y1 e Y2 son cada uno independientemente CR10 o N; R1 y R2 son cada uno independientemente elegidos de H, deuterio, halogeno, -CN, entre otros; R3 es H, deuterio, halogeno, -CN o haloalquilo C1-6; R4 es H, halogeno, -CN, alquilo C1-6, entre otros; R5 es H, alquilo C1-6 y cicloalquilo C3-6, entre otros; Z1, Z2, Z3 y Z4 son cada uno independientemente CH o N; R6 y R7 son cada uno independientemente elegidos de alquilo C1-6; R8 es H, alquilo C1-6, cicloalquilo C3-6 o heterociclilo de 4-8 miembros, entre otros; R9 es H, deuterio o halogeno; R10 es H, deuterio, halogeno, CN, alquilo C1-6 o haloalquilo C1-6; n es 0, 1 o 2; con la condicion de que cuando n es 1, R3 no es H. Tambien se refiere a un metodo para inhibir la actividad de BTK, sintesis de dichos compuestos, compuestos intermediarios, una composicion farmaceutica que lo comprende, y su uso para tratar o prevenir una enfermedad autoinmune, una enfermedad inflamatoria o cancer..
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010993583 | 2020-09-21 | ||
CN202110175357 | 2021-02-07 | ||
CN202111077860 | 2021-09-15 | ||
PCT/CN2021/119056 WO2022057894A1 (en) | 2020-09-21 | 2021-09-17 | Heteroaryl heterocyclic compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20232044A1 true PE20232044A1 (es) | 2023-12-27 |
Family
ID=80775929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023001166A PE20232044A1 (es) | 2020-09-21 | 2021-09-17 | Compuestos heterociclicos de heteroarilo y usos de los mismos |
Country Status (13)
Country | Link |
---|---|
US (2) | US11655254B2 (es) |
EP (1) | EP4214206A1 (es) |
JP (1) | JP2023542040A (es) |
KR (1) | KR20230104125A (es) |
CN (1) | CN116568687A (es) |
AU (1) | AU2021343591A1 (es) |
CA (1) | CA3195525A1 (es) |
CL (1) | CL2023000772A1 (es) |
IL (1) | IL301275A (es) |
MX (1) | MX2023003183A (es) |
PE (1) | PE20232044A1 (es) |
TW (1) | TW202220998A (es) |
WO (1) | WO2022057894A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL301275A (en) * | 2020-09-21 | 2023-05-01 | Hutchison Medipharma Ltd | Heterocyclic heteroaryl compounds and their uses |
WO2023143491A1 (zh) * | 2022-01-28 | 2023-08-03 | 和记黄埔医药(上海)有限公司 | 7,8-二氢-2h-环戊二烯并吡咯并吡嗪酮化合物的合成方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2307413B1 (en) | 2008-07-15 | 2015-09-09 | F. Hoffmann-La Roche AG | Novel phenyl-imidazopyridines and pyridazines |
MX2012012975A (es) | 2010-05-07 | 2013-02-26 | Genentech Inc | Compuestos de piridona y aza-piridona y metodos de uso de los mismos. |
UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
TWI553004B (zh) | 2011-11-03 | 2016-10-11 | 建南德克公司 | 8-氟基呔-1(2h)-酮化合物 |
KR101716011B1 (ko) | 2011-11-03 | 2017-03-13 | 에프. 호프만-라 로슈 아게 | Btk 활성의 억제제인 알킬화된 피페라진 화합물 |
US8722676B2 (en) * | 2011-11-03 | 2014-05-13 | Genentech, Inc. | Bicyclic piperazine compounds |
RU2014126750A (ru) | 2011-12-09 | 2016-01-27 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы тирозинкиназы брутона |
US9326985B2 (en) * | 2013-07-03 | 2016-05-03 | Genentech, Inc. | Heteroaryl pyridone and aza-pyridone amide compounds |
EP3077384B1 (en) | 2013-12-05 | 2017-09-06 | F. Hoffmann-La Roche AG | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
JP6507234B2 (ja) | 2014-10-02 | 2019-04-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ブルトンチロシンキナーゼ(btk)によって介入される障害の処置における使用のためのピラゾールカルボキサミド化合物 |
AU2015328285B2 (en) * | 2014-10-06 | 2019-07-18 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
CN109641892B (zh) | 2016-08-16 | 2021-07-02 | 默克专利有限公司 | 用作可逆btk抑制剂的2-氧代-咪唑并吡啶及其用途 |
TWI673271B (zh) | 2016-12-15 | 2019-10-01 | 瑞士商赫孚孟拉羅股份公司 | 製備btk抑制劑之方法 |
UY37559A (es) | 2017-01-06 | 2018-05-31 | Pharmacyclics Llc | Pirazolo[3,4-b]piridina y pirrolo[2,3-b]piridina como inhibidores de la tirosina quinasa de bruton |
US11100492B2 (en) | 2018-02-19 | 2021-08-24 | Peter Garrett | General purpose re-loadable card aggregation implementation |
CN110256446B (zh) * | 2018-08-01 | 2021-12-14 | 上海海雁医药科技有限公司 | 苯并杂环取代的环戊二烯并[4,5]吡咯并吡嗪-1-酮衍生物及其应用 |
CN115151535A (zh) * | 2020-02-20 | 2022-10-04 | 和记黄埔医药(上海)有限公司 | 杂芳基杂环化合物及其用途 |
IL301275A (en) * | 2020-09-21 | 2023-05-01 | Hutchison Medipharma Ltd | Heterocyclic heteroaryl compounds and their uses |
-
2021
- 2021-09-17 IL IL301275A patent/IL301275A/en unknown
- 2021-09-17 TW TW110134912A patent/TW202220998A/zh unknown
- 2021-09-17 CA CA3195525A patent/CA3195525A1/en active Pending
- 2021-09-17 JP JP2023518212A patent/JP2023542040A/ja active Pending
- 2021-09-17 WO PCT/CN2021/119056 patent/WO2022057894A1/en active Application Filing
- 2021-09-17 AU AU2021343591A patent/AU2021343591A1/en active Pending
- 2021-09-17 CN CN202180063816.7A patent/CN116568687A/zh active Pending
- 2021-09-17 MX MX2023003183A patent/MX2023003183A/es unknown
- 2021-09-17 KR KR1020237011979A patent/KR20230104125A/ko unknown
- 2021-09-17 PE PE2023001166A patent/PE20232044A1/es unknown
- 2021-09-17 EP EP21868716.8A patent/EP4214206A1/en active Pending
-
2022
- 2022-04-25 US US17/728,097 patent/US11655254B2/en active Active
-
2023
- 2023-03-16 CL CL2023000772A patent/CL2023000772A1/es unknown
- 2023-04-17 US US18/301,762 patent/US20230382916A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2023003183A (es) | 2023-04-12 |
CA3195525A1 (en) | 2022-03-24 |
AU2021343591A1 (en) | 2023-05-04 |
KR20230104125A (ko) | 2023-07-07 |
CL2023000772A1 (es) | 2023-09-01 |
JP2023542040A (ja) | 2023-10-04 |
US20220332719A1 (en) | 2022-10-20 |
EP4214206A1 (en) | 2023-07-26 |
IL301275A (en) | 2023-05-01 |
WO2022057894A1 (en) | 2022-03-24 |
CN116568687A (zh) | 2023-08-08 |
US20230382916A1 (en) | 2023-11-30 |
US11655254B2 (en) | 2023-05-23 |
TW202220998A (zh) | 2022-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
PE20220143A1 (es) | Agonistas de glp-1r y usos de los mismos | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
PE20230238A1 (es) | Inhibidores de kras g12c | |
PE20200700A1 (es) | Compuestos macrociclicos y usos de los mismos | |
CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
PE20232044A1 (es) | Compuestos heterociclicos de heteroarilo y usos de los mismos | |
ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
AR086019A1 (es) | COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS | |
UY28578A1 (es) | Derivados de amida | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
CO5590915A2 (es) | Derivados de piperidina como antagonistas nk1 ( receptor del neuropeptido neuroquinina-1) con actividad antagonista superior en tratamientos de trastornos fisiologicos y disminucion de efectos colaterales | |
AR034390A1 (es) | Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
AR048523A1 (es) | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos | |
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
PE20191784A1 (es) | Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos | |
PE20231311A1 (es) | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos |